STMPatch
Rich Mazzola is an experienced finance professional with a strong background in medical technology and consulting. Currently serving as CFO and Co-Founder at Project Medtech since November 2020, Mazzola focuses on the development and delivery of innovative medical technologies. As CFO of Resivant Medical, LLC since July 2023, Mazzola is involved in the development of Cutiva(TM), a next-generation topical skin closure system. Additionally, Mazzola is a Board Member at STMPatch, which aims to enhance health and wellness through equitable vaccine access. Previous roles include independent consultancy and directorial positions at Pease Bell, CPAs, managerial positions at Marcum LLP and Skoda Minotti, and a directorial role at Drips. Mazzola holds a Bachelor of Science degree in Business Administration with a concentration in Accountancy from John Carroll University.
This person is not in the org chart
This person is not in any teams
STMPatch
The SingleTimeMicroneedle Patch allows vaccines to be delivered via transdermal patch that painlessly embeds bodily degradable microneedles in the skin. The microneedles can be programmed for delivery over time and at specific times, requires no refrigeration, and can be self-administered by patients. The core technology of STM is a vaccine patch which can be painlessly applied at a single time on the skin to embed arrays of microneedles (MNs) inside the superficial skin layer (like an invisible tattoo). The MNs are made of a safe biodegradable polymer (used for surgical suture) and pre-programmed to release vaccines repeatedly over a long period, mimicking the effect of multiple prime/booster doses in the traditional vaccination process. The vaccines (including subunit protein-based antigen, vector-based vaccine or mRNAs) are stabilized against high temperatures, thus avoiding the need of cold-chain storage facilities and affirming the antigenicity for a long-term skin embedment. The technology will revolutionize the vaccination process by (1) enabling a high immunogenic efficacy via transdermal delivery, (2) enhancing patient compliance via the use of painless and self-administered skin patch, and (3) removing the logistic/economic burden to store vaccines at high temperatures. This skin patch could also be applied for animal vaccination, offering a high impact on both healthcare and other industry sectors.